Background and Objectives: Vitamin D deficiency during pregnancy is prevalent throughout the world and has been associated with complications in mothers and infants. The aim of this study is to evaluate the efficacy of two doses of vitamin D supplementation (1000 IU/d versus 2000 IU/d) during pregnancy on maternal and cord blood vitamin D status, metabolic, inflammatory and oxidative stress biomarkers as well as maternal and neonatal outcomes (birth size and Apgar score).
Introduction
Vitamin D deficiency or insufficiency is widespread throughout the world in almost all ages and sex subgroups, including pregnant women (1, 2) .The prevalence of vitamin D deficiency among Iranian pregnant women has been reported to range from 60 to 80% (3, 4) . Because of the physiological changes that occur during pregnancy, pregnant women are considered to be the most vulnerable groups for vitamin D deficiency and insufficiency, even in regions with abundant sun exposure (5) (6) (7) (8) .
Vitamin D deficiency might affect both mothers and their neonates, and result in several adverse maternal and neonatal outcomes including gestational diabetes, preeclampsia, preterm delivery, abortion, cesarean, impaired fetal skeletal development, small for gestational age (SGA), low birth weight (LBW), newborn's wheezing and asthma (9) (10) (11) (12) (13) . Vitamin D as an immune modulator has an important role in maternal tolerance to the fetus and correctly embryonic implantation (14) (15) (16) (17) (18) . Indeed, it has been suggested that the regulatory effect of vitamin D on immune function and inflammation is its primary role during pregnancy. Therefore, it seems vitamin D deficiency has modulatory effects on immune function (both innate and adaptive immunity), inflammatory reactions and oxidative stress, which is associated with the presence of aforementioned adverse pregnancy outcomes (19) (20) (21) .
The results of several studies have shown that vitamin D requirement during pregnancy exceeds the recommended value by the Institute of Medicine (IOM; 600 IU/d) (22) to achieve the serum concentrations of >75 nmol/L which is considered sufficient level for all individuals regardless of pregnancy status (23) . In addition, it has been suggested that vitamin D supplementation during pregnancy might reduce the risk of maternal comorbidities attributed to vitamin D deficiency or insufficiency and may help improve neonatal outcomes (24) (25) (26) . However, there are still inconsistencies in the results of trials and considerable controversy surrounding the definition of the cut-off values for vitamin D deficiency and insufficiency during pregnancy (27, 28 
Subjects and Methods
Study design: A double-blind randomized clinical trial is designed among pregnant women attending the outpatient obstetric clinics of three hospitals (with similar culture, education and economic status) in Tehran between February 2017 and January 2018.
During this period of time, pregnant women who refer to the obstetric clinics for prenatal care during the first trimester of gestation at the three hospitals are assessed for eligibility. Eligible subjects are invited to the study and those who are willing to participate by using block randomization are randomly allocated to one of the two vitamin D supplementation groups: (a) 1000 IU/d; and (b) 2000 IU/d. Figure 1 (29) .
Secondary outcomes are changes in maternal cell culture supernatant concentrations of inflammatory cytokines including Interleukin 1 beta (IL-1β), Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) and changes in maternal serum concentrations of high sensitivity C-reactive protein (hs-CRP), intact parathyroid hormone (iPTH), (33)), preeclampsia diagnosed by a blood pressure of 140/90 mmHg or greater and the onset of 24-hour proteinuria ≥0.3 g at >20 weeks of gestation in women without previously hypertension (34) and type of delivery (cesarean section or vaginal delivery). Data collection and variables: Two study visits are done at the first trimester and 34-36 week of gestation. At the first visit, socio-demographic information including age, educational status preexisting diseases, medical history, reproductive characteristics are collected from each participant after describing the objectives and the protocol of the study to her and taking an informed written consent. Moreover, information about duration of sun exposure (the number of minutes/hours that participants have spent in daylight) (35) and life style (dietary intake and physical activity level) are collected using questionnaires by a trained interviewer at the first and last visits.
Dietary intakes are assessed using 24-h recall questionnaire through which the quantity and type of both food and beverages consumed in the previous 24-hour period midnight to midnight on in two days of a week are evaluated. The analysis of 24-h recalls to measure the amount of nutrient intakes is done by using estimated values in household measurements 1 APGAR score includes 5 components including appearance, pulse, grimace, activity, and respiration, each of which is given a score of 0-2 and reported at 1 and 5 minutes after birth. and Nutritionist IV software (First Databank, San Bruno, CA, USA) modified for Iranian foods. Dietary intakes are not the main exposure variable and only will be assessed to adjust the probable differences between two groups. Anthropometric measures and blood pressure: Anthropometric measures and blood pressure of all participants are measured at each antenatal visit. Height is measured only at the first visit. Body mass index (BMI) is calculated as weight in kg divided by height in meters squared.
Routine obstetrical visits are every 4 weeks until 28 weeks, every 2 weeks until 36 weeks, and then weekly until delivery. Information of doctor's visits, health status of participants, and medications is obtained from the mother's records.
Infant's birth weight (g), length (cm) and head circumferences (cm) are recorded for each infant. Laboratory investigations: After 12-14 h of fasting, maternal blood sample (10 mL; 5 mL in tubes without anticoagulant and 5 mL in heparinized falcon) and urine samples are collected at first (first trimester of gestation) and last visit (34-36 weeks of gestation). In addition, cord blood is obtained after clamping following delivery. Samples are sent to the Laboratory of Nutrition Research, NNFTRI, in cold box to separate serum and plasma by centrifugation at 1500 g for 10 minutes at 25Cº. Serum and urine samples are kept in −80˚C until assessment. Fasting serum concentration of glucose, lipid profile, calcium and phosphate are determined by using enzymatic methods (Pars-Azmoon, Tehran, Iran) and an autoanalyzer (Selecta E; Vitalab, Holliston, Netherlands) on the same day of sampling. The intra-and interassay CVs for FSG and lipid concentrations are <5%.
Vitamin D status is determined by measuring the 25(OH) D concentrations, which is the major circulating form of vitamin D in blood (29) . Mothers and cord blood serum concentrations of 25(OH)D are determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (EUROIMMUN) with high correlation of the measurement results with reference methods including LC-MS/MS and HPLC (High-performance liquid chromatography). The inter-assay coefficients of variation (CVs) ranged from 7 to 8.6-and intra-assay CVs ranged from 3.2 to 6.9 %, according to the manufacturer.
Fasting serum insulin is assayed by an ELISA kit (DiaPlus inc., Canada) with intra-and inter-assay CVs are 4.9% and8%, respectively, based on manufacturer's data.
HOMA-IR which is used to evaluate insulin resistance and quantitative insulin sensitivity check index (QUICKI) which is used to evaluate insulin sensitivity are calculated based on suggested formulas (36) .
Serum iPTH concentrations are measured by EUROIMMUN ELISA kit with intra-and inter-assay CVs 2.2%-9.5% and 9.5%-11%, respectively.
Serum hs-CRP is quantified using an ELISA kit (Pars-Azmoon, Tehran, Iran) with intra-and interassay CVs of 2.5% and 4.5%, respectively.
Urinary concentrations of calcium and creatinine are determined using commercial kit and an autoanalyzer. In this study the proportion of urinary calcium to creatinine concentrations is used to adjust for the possible effects of urine dilution or concentration on changes of calcium concentrations in the spot urine sample. Biomarkers of oxidative stress: Serum concentration of malondialdehyde (MDA) and total antioxidant capacity (TAC) are measured to determine oxidative stress. Serum MDA is measured using the Satoh method(37)with minor modifications by Neyestani et al (38) .According to this method, firstly, proteins are precipitated using 20% trichloroacetic acid (TCA). Afterwards, the precipitate is washed with 0.05 M sulfuric acid and then is reacted with thiobarbituric acid (TBA) at 90-100 C for 30 min. In the acidic environment (pH= 2-3), one molecule of MDA binds to two TBA molecules to form a pink complex. Following extraction with n-butanol, absorbance is determined at 532 nm against the blank (n-butanol). Serum concentration of MDA was determined using a standard curve.
Serum, TAC, is evaluated using 2,2"-azinobis (3-ethylbenzothiazoline-6-sulfonate) (ABTS) as a reagent. ABTS under the influence of potassium persulfate is converted to ABTS cation radical (ABTS°+) which is green-blue with maximum absorption at 415nm, 645nm, 734nm, and 815nm. Adding antioxidant solution to this in a given time attenuates color intensity depending on the antioxidant activity and concentration. Therefore, decolorization will be expressed as a percent of ABTS°+ inhibition based on difference of the primary and secondary absorbance divided by primary absorbance multiplied by 100 (39). Inhibition percentage is compared with the antioxidant activity of BSA as standard. Results are expressed as mmol/l of BSA.
Cell separation and culture for cytokine assays:
Peripheral blood mononuclear cells (PBMCs) are separated and cultured with the method described elsewhere (40) . Briefly, PBMCs are separated from fresh heparinized blood using Ficol gradient and then cultured in RPMI 1640 medium (Sigma-Aldrich, Inc., St. Louis, MO) supplemented with 100 U/ml penicillin G, 10 ng/ml streptomycin (both, SigmaAldrich, Inc.), 1% phytohemagglutinin, and 100 ng/ml lipopolysaccharide (Sigma) Human PBMC sare plated at a density of 2×10 6 cells/well in 12-well plates, which are kept for 24 h at 37º C in a 5% humidified CO 2 incubator. Then, cytokines in the cell culture supernatants are measured using commercially available ELISA kits (all from Diaclone, Vienna, Austria) and a microplate reader (StatFax 3200; Awareness Technology, Inc., Palm City, FL, USA). Adherence: The assessment of adherence to the determined vitamin D supplementation regimen is based on the pill counts and maternal self-report (41 
Discussion
A high prevalence (60-80%) of vitamin D deficiency among Iranian pregnant women has been reported by several studies (3) . Although some studies have reported that vitamin D supplementation during pregnancy may reduce the risk of maternal comorbidities attributed to vitamin D deficiency or insufficiency and help to improve neonatal outcomes (24) (25) (26) , there is no general agreement on the optimal dose of vitamin D supplementation in pregnant women (27, 28) . This lack of inconsistency could be attributed to the differences in study design, dose, type, and timing of vitamin D supplementation, and/or the subjects involved in the study with heterogeneous vitamin D status, and/or methodological differences. It is noteworthy that the effectiveness of the current recommendation of 1000 IU vitamin D/d during pregnancy made by the Ir MOH has not been documented by far. The current study attempts to evaluate the effectiveness of two different doses of vitamin D by using a wide spectrum of maternal and neonatal biomarkers. The results of this study could be potentially valuable for further development of guidelines and policy-making on vitamin D supplementation during pregnancy. 
Strengths of the study
The advantages of the present study are as follows: 1) the randomized clinical design,2) initiating vitamin D supplementation early in pregnancy until delivery, 3) evaluating the confounding factors (diet, physical activity level, sun exposure), 4) Assessing the metabolic, oxidative stress and inflammatory markers in maternal and cord blood samples.
The results of the present study will help clinicians regarding administration an optimal dose of vitamin D supplementation during pregnancy and also will help guide the public health policymaker to revise the currently used vitamin D supplementation protocol among pregnant women.
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